Pomegra
Healthcare
NOTABLE
2d ago5 min read
PepGen (PEPG) Surges 90% on DM1 Trial Data
PepGen shares jumped about 90% after its DM1 drug PGN-EDODM1 delivered 46.5% mean splicing correction in a Phase 2 trial, the highest in multi-dose studies.
Pomegra Newswire
Healthcare News
Healthcare, pharma, and biotech market news: drug approvals, trial results, and the deals reshaping the sector.
AllMarketsEconomyBusiness & EarningsTechnologyHealthcarePolicy & RegulationGeopoliticsCommunity & Media
Healthcare
NOTABLE
3d ago6 min read
Eli Lilly (LLY) Rises 2% on Jefferies $1,700 Target
Eli Lilly shares rose about 2% as Jefferies set a Street-high $1,700 target and oral obesity pill Foundayo posted positive Phase 3 sleep apnea data on Monday.
Healthcare
MAJOR
Nov 65 min read
Moderna (MRNA) Hits 52-Week High Before Q3 Earnings
Moderna stock jumped 13% to $258.38 before its Q3 earnings, lifted by a WHO Ebola vaccine nod and cancer-vaccine momentum, extending a 600%-plus gain this year.
Healthcare
MAJOR
Nov 45 min read
CVS Health split: Aetna and drugstores to part by 2028
CVS Health (CVS) plans to separate its drugstore chain from Aetna and Caremark into two public companies by early 2028, and shares rose after hours.
Healthcare
NOTABLE
Nov 35 min read
Revvity (RVTY) Jumps After Raising 2026 EPS Outlook
Revvity shares rose about 7% premarket on Nov. 3 after the life-sciences group lifted its 2026 adjusted EPS outlook to $5.40-$5.45 on a third-quarter revenue beat.
Healthcare
MAJOR
Nov 35 min read
Eli Lilly Tops $1T as Novo Nordisk Reports Wednesday
Eli Lilly's market value sits above $1 trillion on Zepbound and Mounjaro sales and a raised outlook, as Novo Nordisk reports Wednesday under obesity price pressure.
Healthcare
MAJOR
Nov 35 min read
IDEXX (IDXX) Surges 22% on Q3 Beat and Higher 2026 Outlook
IDEXX Laboratories (IDXX) stock jumped about 22% after third-quarter earnings of $4.01 a share topped estimates and the company raised its 2026 outlook.
Healthcare
MAJOR
Nov 25 min read
Illumina Stock Plunges 19%, Worst Day Since 2016
Illumina (ILMN) stock fell 18.6% to $235.99 on Oct. 30, its worst session since 2016, despite a Q3 earnings beat and a raised full-year 2026 revenue forecast.
Healthcare
MAJOR
Oct 305 min read
Regeneron REGN Surges to Two-Year High on Q3 Beat
Regeneron stock jumped more than 8% premarket to a two-year high after Q3 2026 revenue rose 36% to $5.12 billion and adjusted EPS beat estimates by $3.82.
Healthcare
MAJOR
Oct 264 min read
Moderna Stock Falls 8% After Melanoma Vaccine Data Leak
Moderna (MRNA) shares fell another 8% on Monday after leaked melanoma vaccine data showed a 42% cut in recurrence or death risk, extending a selloff in biotech cancer stocks.
Healthcare
NOTABLE
Oct 264 min read
Surgery Partners (SGRY) Jumps 21% on $6B Bon Secours Bid
Surgery Partners stock surged about 21% premarket as Bon Secours Mercy Health neared a roughly $6B majority-stake deal, including debt, for the Bain-backed chain.
Healthcare
MAJOR
Oct 224 min read
Moderna Falls 25% as Leaked Melanoma Data Spooks Investors
Moderna shares fell as much as 25% after early-leaked Phase 3 melanoma vaccine data showed a 42% cut in recurrence risk, below Wall Street's lofty expectations.
Healthcare
NOTABLE
Oct 225 min read
Dexcom (DXCM) Falls 6% After Abbott Cuts Diabetes Outlook
Dexcom (DXCM) fell about 6% on Oct. 21 after rival Abbott cut its diabetes care growth outlook, making it a top S&P 500 decliner as the index gained.
Healthcare
MAJOR
Oct 215 min read
Moderna Stock Jumps 7% Ahead of Madrid Melanoma Data
Moderna rose 7% to $241.89 and Bristol Myers Squibb 5% as biotech cancer stocks rallied before Phase 3 melanoma vaccine data in Madrid on October 24.
Healthcare
MAJOR
Oct 216 min read
Intuitive Surgical (ISRG) Falls After Q3 2026 Beat
Intuitive Surgical shares fell 7% to 13% after hours on Oct. 20 as a $450 million antitrust settlement and planned da Vinci price cuts overshadowed a Q3 beat.
Healthcare
NOTABLE
Oct 205 min read
Eli Lilly stock hits record $1,311 before Q3 earnings
Eli Lilly (LLY) shares hit a record near $1,311 after Goldman raised its target to $1,413, a day after BofA, ahead of its Oct. 29 third-quarter report.
Healthcare
NOTABLE
Oct 145 min read
UnitedHealth (UNH) Q3 2026: EPS Beats, Guidance Raised
UnitedHealth (UNH) beat Q3 2026 earnings with $4.69 adjusted EPS and raised its full-year outlook to at least $20.50 per share, its third increase this year.
Healthcare
NOTABLE
Oct 135 min read
J&J Q3 2026: Talc Charge Cuts Profit 96% as Outlook Rises
Johnson & Johnson (JNJ) shares slipped after a $5.5B talc settlement charge cut Q3 profit 96%, though sales and adjusted EPS beat and 2026 guidance rose.
Healthcare
NOTABLE
Oct 135 min read
Biogen (BIIB) Hits 52-Week High on JPMorgan Upgrade
Biogen (BIIB) stock hit a 52-week high after JPMorgan upgraded it to Overweight with a $300 target, citing a run of late-stage trial readouts through 2027.
Healthcare
NOTABLE
Oct 124 min read
Moderna Jumps 14% on Federal Cancer Vaccine Push
Moderna rose 14% to $225, its highest since January 2022, as a planned federal cancer vaccine push also lifted Pfizer, BioNTech and Merck shares on Friday.
Healthcare
MAJOR
Oct 125 min read
UnitedHealth Q3 2026 Earnings Hinge on Medicare Margins
UnitedHealth (UNH) reports Q3 2026 earnings on Oct. 13, with Medicare Advantage margins in focus after Humana's 11.6% surge on 2027 Medicare star ratings.
Healthcare
MAJOR
Oct 95 min read
Humana (HUM) Jumps 15% on 2027 Medicare Star Ratings
Humana shares surged about 15% after its largest Medicare Advantage contract rose to 4 stars, while Alignment Healthcare fell more than 20% on a downgrade.
Healthcare
NOTABLE
Oct 84 min read
Haemonetics (HAE) Jumps 17% as CSL Plans Full U.S. Rollout
Haemonetics shares rose as much as 17% premarket Thursday after CSL said it will deploy NexSys PCS plasma devices at all U.S. centers by the end of 2027.
Healthcare
NOTABLE
Oct 75 min read
Option Care Health (OPCH) $5.8B Take-Private Explained
McKesson (MCK) and CD&R will buy Option Care Health for $32.05 a share in a $5.8 billion take-private, lifting OPCH stock about 33% on Tuesday, Oct. 6.
Healthcare
NOTABLE
Oct 74 min read
Moderna Stock Falls 6% After Nasdaq-100 Rally
Moderna (MRNA) shares fell about 6% on profit-taking after a 52-week high, days before the biotech replaces Warner Bros. Discovery in the Nasdaq-100 on Oct. 9.
Healthcare
MAJOR
Oct 65 min read
Option Care (OPCH) Agrees $5.8B McKesson, CD&R Buyout
McKesson and CD&R will take Option Care Health private at $32.05 a share, a $5.8 billion deal, after the stock jumped 21% on reports of advanced talks.
Healthcare
NOTABLE
Oct 65 min read
AstraZeneca Closes $2B Summit Therapeutics Stake
AstraZeneca completed its $2 billion equity investment in Summit Therapeutics, lifting SMMT about 17% premarket as the cancer-drug tie-up moves to trials.
Healthcare
MAJOR
Oct 55 min read
Vaxcyte Surges 50% as VAX-31 Wins Phase 3 Trial
Vaxcyte (PCVX) shares jumped about 50% after VAX-31 met every primary endpoint in a pivotal Phase 3 trial against Pfizer's Prevnar 20 and Merck's Capvaxive.
Healthcare
MAJOR
Sep 304 min read
Liquidia (LQDA) Plunges After Patent Loss to UTHR
Liquidia shares fell more than 50% after a Delaware court found Yutrepia infringed a United Therapeutics patent, while UTHR stock rose 12% on the ruling.
Healthcare
NOTABLE
Sep 304 min read
Moderna (MRNA) Drops 6% as Citi Downgrades to Sell
Moderna shares fell about 6% to near $190 after Citi cut the stock to Sell with an $80 target, saying a 223% rally overshot what cancer vaccine sales can justify.
Why is healthcare news different?
Healthcare investing runs on binary events. A drug trial readout or an FDA approval decision can double a biotech or cut it in half overnight, because a small company's whole valuation may rest on one molecule. The desk covers those catalysts - trial results, approvals, and the label details that decide a drug's market - alongside the steadier earnings of large pharma, insurers, and device makers.
The sector is also the classic defensive play: people need medicine in every economy, so healthcare earnings hold up when cyclical sectors roll over. Coverage links each story to the wiki entries on the science terms and the sector mechanics, so a headline about a Phase 3 miss explains itself.
Frequently Asked
Why are biotech stocks so volatile?
Small biotech valuations often rest on one or two drug candidates, so trial results and FDA decisions can reprice the whole company overnight.